Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRIMIPRAMINE

Form:

10 of 10 products shown

5 general benefit · 5 not a benefit

Other products in the same Health Canada class (N06AA) — coverage varies; not interchangeable

  • Amitriptyline (Elavil): general benefit
  • Clomipramine (Anafranil Tab): general benefit
  • Desipramine (Pertofrane): general benefit, Not a benefit
  • Doxepin (Sinequan): general benefit, Not a benefit
  • Imipramine (Tofranil): general benefit, Not a benefit
  • Nortriptyline (Aventyl): general benefit

17 more in the class list below

Trimipramine · DIN 00740799 · 12.5mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trimipramine · DIN 00740799 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2014-06-12 · brand TRIMIPRAMINE · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 12.5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Trimipramine: Formulary list price $0.2203/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8065 · Verify on the e-Formulary ↗ (DIN 00740799)

Source record
DIN 00740799: Trimipramine Raw flags: sec3=Y Item: 281604024; group id 473; item number 1189; lccId None; manufacturer id AAP Source form: Tab; strength: 12.5mg Recorded listing: General benefit Source prices (unrounded): $0.2203; ministry $0.2203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00740799 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8065
Interchangeable products
Surmontil · DIN 01926357 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00740799
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trimipramine · DIN 00740802 · 25mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trimipramine · DIN 00740802 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2011-01-17 · brand TRIMIPRAMINE · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 25 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Trimipramine: Formulary list price $0.3025/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3025 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8066 · Verify on the e-Formulary ↗ (DIN 00740802)

Source record
DIN 00740802: Trimipramine Raw flags: sec3=Y Item: 281604023; group id 473; item number 1190; lccId None; manufacturer id AAP Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.3025; ministry $0.3025 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00740802 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8066
Interchangeable products
Surmontil · DIN 01926322 · not recorded
Shortage status: discontinued (2016-08-18, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00740802
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trimipramine · DIN 00740810 · 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trimipramine · DIN 00740810 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2011-05-09 · brand TRIMIPRAMINE · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 50 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Trimipramine: Formulary list price $0.5922/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5922 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8067 · Verify on the e-Formulary ↗ (DIN 00740810)

Source record
DIN 00740810: Trimipramine Raw flags: sec3=Y Item: 281604022; group id 473; item number 1191; lccId None; manufacturer id AAP Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.5922; ministry $0.5922 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00740810 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8067
Interchangeable products
Surmontil · DIN 01926330 · not recorded
Shortage status: resolved shortage (ended 2025-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00740810
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trimipramine · DIN 02070987 · 75mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trimipramine · DIN 02070987 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-04-08 · brand TRIMIPRAMINE · ATC N06AA06 TRIMIPRAMINE · form Capsule · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 75 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Trimipramine: Formulary list price $0.7972/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7972 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15592 · Verify on the e-Formulary ↗ (DIN 02070987)

Source record
DIN 02070987: Trimipramine Raw flags: sec3=Y Item: 281604033; group id 473; item number 1188; lccId None; manufacturer id AAP Source form: Cap; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.7972; ministry $0.7972 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02070987 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15592
Interchangeable products
Surmontil · DIN 01926349 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02070987
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trimipramine · DIN 00740829 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trimipramine · DIN 00740829 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2012-01-06 · brand TRIMIPRAMINE · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 100 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Trimipramine: Formulary list price $1.0107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8106 · Verify on the e-Formulary ↗ (DIN 00740829)

Source record
DIN 00740829: Trimipramine Raw flags: sec3=Y Item: 281604021; group id 473; item number 1192; lccId None; manufacturer id AAP Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $1.0107; ministry $1.0107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00740829 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8106
Interchangeable products
Surmontil · DIN 01926284 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00740829
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Surmontil · DIN 01926357 · 12.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.Discontinued 2005-08-01 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Surmontil · DIN 01926357 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-08-01 · brand SURMONTIL 12.5 · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 12.5 MG · company Aventis pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Surmontil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13174 · Verify on the e-Formulary ↗ (DIN 01926357)

Source record
DIN 01926357: Surmontil Raw flags: notABenefit=Y, sec3=Y Item: 281604024; group id 473; item number 1189; lccId None; manufacturer id RPP Source form: Tab; strength: 12.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926357 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13174
Interchangeable products
Trimipramine · DIN 00740799 · $0.2203
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926357
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.

Surmontil · DIN 01926322 · 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.Discontinued 2006-07-28 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Surmontil · DIN 01926322 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-07-28 · brand SURMONTIL · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 25 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Surmontil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12835 · Verify on the e-Formulary ↗ (DIN 01926322)

Source record
DIN 01926322: Surmontil Raw flags: notABenefit=Y, sec3=Y Item: 281604023; group id 473; item number 1190; lccId None; manufacturer id RPP Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926322 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12835
Interchangeable products
Trimipramine · DIN 00740802 · $0.3025
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926322
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.

Surmontil · DIN 01926330 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.Discontinued 2006-07-28 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Surmontil · DIN 01926330 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-07-28 · brand SURMONTIL · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 50 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Surmontil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12751 · Verify on the e-Formulary ↗ (DIN 01926330)

Source record
DIN 01926330: Surmontil Raw flags: notABenefit=Y, sec3=Y Item: 281604022; group id 473; item number 1191; lccId None; manufacturer id RPP Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926330 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12751
Interchangeable products
Trimipramine · DIN 00740810 · $0.5922
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926330
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2006-07-28 — choose a marketed DIN from the same-category list.

Surmontil · DIN 01926349 · 75mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.Discontinued 2005-08-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Surmontil · DIN 01926349 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-08-01 · brand SURMONTIL 75 · ATC N06AA06 TRIMIPRAMINE · form Capsule · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 75 MG/CAP · company Aventis pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Surmontil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12994 · Verify on the e-Formulary ↗ (DIN 01926349)

Source record
DIN 01926349: Surmontil Raw flags: notABenefit=Y, sec3=Y Item: 281604033; group id 473; item number 1188; lccId None; manufacturer id RPP Source form: Cap; strength: 75mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926349 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12994
Interchangeable products
Trimipramine · DIN 02070987 · $0.7972
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926349
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.

Surmontil · DIN 01926284 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.Discontinued 2005-08-01 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Surmontil · DIN 01926284 Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-08-01 · brand SURMONTIL 100 · ATC N06AA06 TRIMIPRAMINE · form Tablet · route Oral · ingredients TRIMIPRAMINE (TRIMIPRAMINE MALEATE) 100 MG · company Aventis pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Surmontil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12224 · Verify on the e-Formulary ↗ (DIN 01926284)

Source record
DIN 01926284: Surmontil Raw flags: notABenefit=Y, sec3=Y Item: 281604021; group id 473; item number 1192; lccId None; manufacturer id RPP Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926284 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12224
Interchangeable products
Trimipramine · DIN 00740829 · $1.0107
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926284
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-08-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS TRIMIPRAMINE (trimipramine) is indicated in the drug treatment of depressive illness. It is effective in endogenous depression. https://pdf.hres.ca/dpd_pm/00010672.PDF PM date: not printed or not captured Source product: TRIMIPRAMINE; DIN 00740799; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Trimipramine · DIN 00740802 Shortage status: discontinued (2016-08-18, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00740802

Check this DIN again

Other review policies

For Surmontil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026